(Adds details of the tests)
SEOUL, June 1 (Reuters) - South Korea's Celltrion Inc
068270.KS said on Monday its experimental treatment of
COVID-19 demonstrated a 100-fold reduction in viral load of the
disease in animal testing.
Drugmakers worldwide are rushing to develop treatments and
vaccines for the illness that has caused more than 371,000
deaths globally.
The pre-clinical study of the drug showed improved recovery
in runny nose, cough and body aches after the first day of
treatment, and clearing of lung inflammation within six days,
the company said in a statement.
Celltrion has research experience with other types of
coronavirus conditions such as Middle East Respiratory Syndrome
(MERS). It hopes to commence first in-human clinical trials for
the COVID-19 treatment in July, said Kwon Ki-Sung, head of the
firm's research and development unit.
"(Celltrion) has the capability to roll out mass production
of the therapeutic antibody treatment once it is ready," Kwon
said.
Shares in Celltrion traded up 4.2% on Monday morning in
Seoul compared to the benchmark KOSPI's .KS11 1.4% climb.
(Reporting by Joyce Lee; Editing by Himani Sarkar and
Christopher Cushing)
((jungyoon.lee@tr.com; +82 2 6936 1467;))